Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an announcement.
On August 8, 2025, Haleon PLC announced the purchase and cancellation of 1,330,960 ordinary shares as part of the second tranche of its share buyback program initiated on July 31, 2025. This transaction, executed on August 7, 2025, is part of Haleon’s strategy to optimize its capital structure and potentially enhance shareholder value. Following this transaction, the company’s registered share capital consists of 8,980,592,548 ordinary shares, with 8,976,712,343 shares having voting rights. This move may impact stakeholders by altering the shareholding structure and potentially affecting market perceptions of the company’s financial health.
The most recent analyst rating on (HLN) stock is a Buy with a $13.40 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score of 65 reflects a mixed outlook. Strong financial performance and strategic investments are offset by bearish technical signals and regional sales challenges, particularly in North America. The company’s valuation is moderate, aligning with its growth prospects. Continued focus on innovation and market expansion could enhance its position, but near-term challenges need to be addressed.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers a diverse product portfolio across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are built on a foundation of scientific innovation and deep human understanding.
Average Trading Volume: 15,000,667
Technical Sentiment Signal: Sell
Current Market Cap: $42B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.